NADH alone in a placebo-controlled crossover pilot
Forsyth LM et al. · 1999 · Annals of Allergy, Asthma & Immunology
Indexed 2026-11-12.
Reported findings and study design
Reported findings
Double-blind crossover trial of oral NADH 10 mg daily and placebo for four weeks each with a four-week washout.
Dose, route and schedule
Double-blind crossover trial of oral NADH 10 mg daily and placebo for four weeks each with a four-week washout.
Protocol source ↗ · Original article abstract
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Reported response | 8/26 (31%) during NADH and 2/26 (8%) during placebo met the study’s response criteria. |
Small, short crossover study using a historical CFS definition and a study-specific response measure.
Source for these results ↗ · Reviewed 2026-11-12
For research and education. Consult a qualified clinician for medical advice.
Study limitations and source details
Study limitations
- Small, short crossover study using a historical CFS definition and a study-specific response measure.
Source access
Double-blind crossover trial of oral NADH 10 mg daily and placebo for four weeks each with a four-week washout.
Source reviewed 2026-11-12.
Citation and original source
Original source: Forsyth LM et al.. NADH alone in a placebo-controlled crossover pilot Annals of Allergy, Asthma & Immunology 1999.
Molekul research summary: https://molekul.io/research/nadh-forsyth-1999. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry